Beyond FRAX®: It's Time to Consider “Sarco-Osteopenia”

Binkley, Neil; Buehring, Bjoern

doi:10.1016/j.jocd.2009.06.004

Cited by 174 publications

(108 citation statements)

References 25 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of frailty in the general elderly population was found to be 16-43% when using the Clinical Frailty Scale of the Canadian Study of Health and Aging (CSHA CFS), a screening tool for frailty [4,11,12]. Sarcopenia and frailty have been found more frequently in elderly individuals with chronic diseases such as chronic lung diseases (e.g., chronic obstructive pulmonary disease), cardiovascular diseases, peripheral vascular diseases, diabetes, chronic kidney disease, liver cirrhosis, and osteoporosis [13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study

et al. 2018

View full text Add to dashboard Cite

Background: Sarcopenia and frailty are found in up to one-third of the general elderly population. Both are associated with major adverse health outcomes such as nursing home placement, disability, decreased quality of life, and death. Data on the frequency of both syndromes in Parkinson’s disease (PD), however, are very limited. Objective: We aimed to screen for sarcopenia and frailty in PD patients and to assess potential associations of both geriatric syndromes with demographic and clinical parameters as well as quality of life. Methods: In this observational, cross-sectional study, we included 104 PD patients from a tertiary center and 330 non-PD controls from a population-based cohort aged > 65 years. All groups were screened for sarcopenia using the SARC-F score and for frailty using the Clinical Frailty Scale of the Canadian Study of Health and Aging (CSHA CFS). Prevalence rates of sarcopenia and frailty were also assessed in 18 PD patients from a population-based cohort aged > 65 years. Moreover, PD patients from the tertiary center were evaluated for motor and non-motor symptoms, quality of life, and dependency. Results: The prevalence of sarcopenia was 55.8% (95% CI: 46.2–64.9%) in PD patients from the tertiary center and 8.2% (5.7–11.7%; p < 0.001) in non-PD controls. Frailty was detected in 35.6% (27.0–45.2%) and 5.2% (3.2–8.1%; p < 0.001). Prevalence rates for sarcopenia and frailty were 33.3% (16.1–56.4%; p = 0.004) and 22.2% (8.5–45.8%; p = 0.017) in the community-based PD sample. Both sarcopenia and frailty were significantly associated with longer disease duration, higher motor impairment, higher Hoehn and Yahr stages, decreased quality of life, higher frequency of falls, a higher non-motor symptom burden, institutionalization, and higher care levels in PD patients from a tertiary center compared to not affected PD patients (all p < 0.05). Conclusions: Both frailty and sarcopenia are more common in PD patients than in the general community and are associated with a more adverse course of the disease. Future studies should look into underlying risk factors for the occurrence of sarcopenia and frailty in PD patients and into adequate management to prevent and mitigate them.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…As noted above, it seems likely that sarcopenia, the agerelated decline in muscle mass and function, [15] is a major contributor to the increased falls and fracture risk seen with advancing age [5,16,17]. However, despite burgeoning interest in and expansion of pathophysiologic knowledge regarding sarcopenia, there has been virtually no translation of this entity to clinical care.…”

Section: Introductionmentioning

confidence: 99%

What’s in a name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome?”

2013

View full text Add to dashboard Cite

Sarcopenia and osteoporosis are age-related declines in the quantity and quality of muscle and bone respectively, with shared pathogeneses and adverse health consequences. Both absolute and relative fat excess, i.e., obesity and sarcopenic obesity, contribute to disability, falls, and fractures. Rather than focusing on a single component, i.e., osteoporosis, sarcopenia, or obesity, we realized that an opportunity exists to combine clinical factors, thereby potentially allowing improved identification of older adults at risk for disability, falls, and fractures. Such a combination could be termed dysmobility syndrome, analogous to the approach taken with metabolic syndrome. An arbitrary score-based approach to dysmobility syndrome diagnosis is proposed and explored in a small cohort of older adults. Further evaluation of such an approach in large populationbased and prospective studies seems warranted.

show abstract

“…This condition is an emerging health problem that is characterized by the simultaneous manifestation of excess body fat and low muscle mass and/or strength, and has been described by Roubenoff [8] as the confluence of 2 epidemics: aging and obesity. The terms sarco-osteopenia and sarco-osteoporosis were initially introduced by Binkley and Buehring [9] ; they were the first to propose that patients with both low bone and muscle masses or performance should be diagnosed with this condition.…”

mentioning

confidence: 99%

Association between Sarcopenic Obesity and Bone Mineral Density in Middle-Aged and Elderly Korean

Chung¹,

Hwang

Shin

et al. 2015

Ann Nutr Metab

View full text Add to dashboard Cite

Objectives: To identify the prevalence of osteosarcopenic obesity and to evaluate the association between sarcopenic obesity and bone mineral density in middle-aged and elderly Korean. Methods: This study included 3,385 males and 4,064 females (age ≥50 years and in the stage of menopause) who participated in the Korean National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011. The cutoff value for sarcopenia was 7.26 kg/m² for men and 5.45 kg/m² for female. The fat mass was >30% for men and 40% for female; these values were used to define obesity. Based on the combination of sarcopenia and obesity status, all subjects were classified as sarcopenic obese (SO), sarcopenic nonobese (SNO), nonsarcopenic obese (NSO), or nonsarcopenic nonobese. Results: The incidence rates of sarcopenia, sarcopenic obesity, and osteosarcopenic obesity were 31.5, 5.1, and 4.1%, respectively. Following adjustment, the ORs for osteoporosis were 8.67 in the SO group (95% CI 4.19-17.94), 3.85 in the SNO group (95% CI 2.61-5.67), and 1.88 in the NSO group (95% CI 0.72-4.91) in men and 2.93 in the SO group (95% CI 1.99-4.32), 1.71 in the SNO group (95% CI 1.31-2.23), and 0.58 in the NSO group (95% CI 0.43-0.78) in women. Conclusions: Sarcopenic obesity is associated with the development of osteoporosis among the middle-aged and elderly Korean population.

show abstract

Beyond FRAX®: It's Time to Consider “Sarco-Osteopenia”

Cited by 174 publications

References 25 publications

Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study

Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study

What’s in a name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome?”

Association between Sarcopenic Obesity and Bone Mineral Density in Middle-Aged and Elderly Korean

Contact Info

Product

Resources

About